Patients were randomly assigned in a @:@:@:@ ratio to receive ledipasvir and sofosbuvir in a fixed-dose combination tablet once daily for @ weeks , ledipasvir-sofosbuvir plus ribavirin for @ weeks , ledipasvir-sofosbuvir for @ weeks , or ledipasvir-sofosbuvir plus ribavirin for @ weeks .